MindMaze Therapeutics Holding S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RLFTY research report →
Price Chart
About the company
MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. The company offers MindPod system, a supervised in-clinic neurorehabilitation system designed to initiate and intensify the recovery journey; MindMotion GO, which extends protocolized neurotherapeutics into outpatient and home settings; MindMotion Companion, an application that manages prescription, monitoring and documentation across MindMaze Therapeutics' neurotherapeutics ecosystem; and the patient app, a patient-facing mobile application, that supports clinic-to-home continuity by making prescribed therapy easy to follow outside the clinic. It also provides Izar hand therapy device which supports fine motor rehabilitation; Physilog sensor, a wearable inertial sensing device designed to quantify human movement; toaprun, a training for Parkinson's therapy-reimagined through play.
- CEO
- Zach W. Henderson
- IPO
- 2025
- Employees
- 10
- HQ
- Geneva, GE, CH
Get TickerSpark's AI analysis on RLFTY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
Latest fiscal year · YoY change
- Revenue
- $642.00K-92.4%
- Gross Profit
- $591.00K-89.9%
- Op Income
- $-10,515,000
- Net Income
- $-9,906,000+42.1%
- EPS
- $-0.79+42.3%
- OCF Growth
- -147.2%
- FCF Growth
- -134.1%
- 52W High
- $4.90
- 52W Low
- $0.17
- 50D MA
- $0.94
- 200D MA
- $1.24
- Beta
- 3.02
- RSI (14)
- 41
- Avg Volume
- 45
No earnings-call transcripts are available for RLFTY yet.
- Free Float
- 76.6%
- Shares Outstanding
- 157.60M
- Float Shares
- 37.20M
Our RLFTY coverage
Recent articles, reports, and earnings notes.
No research on RLFTY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RLFTY report →Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032
accessnewswire.com · Oct 29
Relief Therapeutics Publishes 2025 Half-Year Report
accessnewswire.com · Aug 14
Relief Therapeutics Advances Publication of 2025 Half-Year Report
accessnewswire.com · Aug 11
Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze
accessnewswire.com · Jul 29
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
accessnewswire.com · Jun 20
Relief Therapeutics Announces Results of Annual General Meeting
accessnewswire.com · Jun 12
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
accessnewswire.com · May 22
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
accessnewswire.com · May 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.